Developing an HIV vaccine is a difficult scientific challenge, but remains a critical priority. This handout provides an update on HIV vaccine research and a summary of results from the efficacy trials that have been conducted to date, and it…
Treatment Action Group (TAG) recognizes the importance of intentionally engaging the community broadly in our advocacy efforts, and we believe that the community should always be at the forefront of advocacy and research. Meaningful community engagement builds trust and fosters…
HIV advocacy laid the foundation for much of the work we do today. This handout was developed in collaboration with the Black AIDS Institute, HIV Vaccine Trials Network, and Southern AIDS Coalition. The handout provides a summary of the history…
HIV prevention research continues to rapidly evolve. The availability of pre-exposure prophylaxis (PrEP) has necessitated the development of new approaches to testing the efficacy of additional biomedical HIV prevention options. This handout was developed in collaboration with the Black AIDS…
HIV-specific broadly neutralizing antibodies (bNAbs) could have a role in treating, preventing, or even curing HIV. Some HIV-specific bNAbs are already being tested in clinical trials, both for prevention and treatment. This handout was developed in collaboration with the Black…
Long-acting pre-exposure prophylaxis (PrEP) will be a groundbreaking HIV prevention tool. The approach provides an option to receive intermittent doses of PrEP instead of taking daily pills. This handout provides an update on the development of long-acting PrEP and future…
HIV science can be difficult to understand. This handout explains some of the unique scientific challenges presented by HIV. The handout was developed in collaboration with the Black AIDS Institute, HIV Vaccine Trials Network, and Southern AIDS Coalition.
These three fact sheets were developed by TAG in partnership with the COVID-19 Prevention Network (CoVPN) and the Black AIDS Institute (BAI), and they aim to foster community understanding of COVID-19 vaccine research and development, as well as highlight community perspectives on the topic.
Delivering on the Promise of Long-Acting Forumulations delves deep into the development of long-acting formulations for the treatment and prevention of infectious diseases like HIV, tuberculosis, hepatitis C, and malaria. Long-acting medications have become common for conditions such as osteoporosis and schizophrenia, and they're even used for birth control.
Abraham Johnson, TAG's Community Engagement Officer, presented this webinar with Carl Dieffenbach, Director of the Division of AIDS at the National Institute for Allergy and Infectious Diseases (NIAID), where he provided an update on the future of biomedical HIV prevention research.